AptaBio Therapeutics Inc. (KOSDAQ: 293780)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,570.00
-170.00 (-2.52%)
Dec 19, 2024, 12:30 PM KST
-22.16%
Market Cap 165.59B
Revenue (ttm) 2.91B
Net Income (ttm) -20.17B
Shares Out 26.88M
EPS (ttm) -896.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 45,413
Open 6,680.00
Previous Close 6,740.00
Day's Range 6,430.00 - 6,730.00
52-Week Range 4,930.00 - 15,490.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Apr 30, 2025

About AptaBio Therapeutics

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical nee... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 32
Stock Exchange KOSDAQ
Ticker Symbol 293780
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.